Fortrea Holdings Inc

Análisis de la acción Fortrea Holdings Inc (FTRE)

$22.420

-0.070 (-0.31%)Al cierre

Loading chart…
Máximo
23.040
Apertura
22.490
Precio medio ponderado por volumen
22.61
Volumen
1.65M
Capitalización
2.04B
Mínimo
22.380
Importe
37.37M
EV/EBITDA, TTM
20.85

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

www.fortrea.com

Análisis de IA of Fortrea Holdings Inc (FTRE)

Comprar

Fortrea Holdings Inc is a good buy right now, trading at $22.49 with a forward P/E of 12.14, indicating potential for growth relative to earnings. The stock has shown a strong 1-year change of +115.83%, reflecting significant appreciation over the past year. However, the main risk is the insider selling, which has increased by 267.54% over the last month, suggesting potential concerns about the company's future performance.

Métricas de valoración

El PER previsto actual de Fortrea Holdings Inc (FTRE) es 12.14, frente a su media de 5 años de 22.69.

PER previsto

Valor razonable
Media 5A P/E
22.69
P/E actual
12.14
Sobrevalorada
38.24
Infravalorada
7.13

EV/EBITDA previsto

Sobrevalorado
Media 5A EV/EBITDA
12.58
EV/EBITDA actual
20.85
Sobrevalorada
18.69
Infravalorada
6.47

Precio/ventas previsto

Valor razonable
Media 5A P/S
0.64
P/S actual
0.79
Sobrevalorada
0.92
Infravalorada
0.35

Escenarios de precio de Alphio AI para FTRE

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%FTRE

$4.04

Precio del escenario

B

Base

Base · 50%FTRE

$3.61

Precio del escenario

B

Bajista

Bajista · 25%FTRE

$2.97

Precio del escenario

Ballenas con FTRE en cartera

B

Beck, Mack & Oliver LLC

+ Con en carteraFTRE

+1.99%

Rentabilidad a 3 meses

C

Corvex Management LP

+ Con en carteraFTRE

+0.72%

Rentabilidad a 3 meses

S

Sessa Capital IM, L.P.

+ Con en carteraFTRE

-14.11%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-02 (ET)

07:30:00

Fortrea Acquires Worldwide's Early Phase Services Division for $45M

2026-07-29 (ET)

07:00:00

Raises FY26 Adjusted EBITDA Outlook to $205M-$220M

2026-06-26 (ET)

09:30:00

Nasdaq Futures Decline as Tech Stocks Weaken

07:30:00

Fortrea Appoints Jason Knoblauch as CFO

Noticias

Preguntas frecuentes sobre FTRE, respondidas por Alphio AI

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Fortrea Holdings Inc is a good buy right now, trading at $22.49 with a forward P/E of 12.14, indicating potential for growth relative to earnings. The stock has shown a strong 1-year change of +115.83%, reflecting significant appreciation over the past year. However, the main risk is the insider selling, which has increased by 267.54% over the last month, suggesting potential concerns about the company's future performance.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar